Equities

Genedrive PLC

Genedrive PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.63
  • Today's Change0.025 / 1.56%
  • Shares traded11.40m
  • 1 Year change-88.56%
  • Beta-1.1123
Data delayed at least 20 minutes, as of Jun 14 2024 16:16 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.

  • Revenue in GBP (TTM)272.00k
  • Net income in GBP-5.00m
  • Incorporated2007
  • Employees43.00
  • Location
    Genedrive PLC48 Grafton StreetMANCHESTER M13 9XXUnited KingdomGBR
  • Phone+44 161 989 0245
  • Fax+44 161 989 0262
  • Websitehttp://www.genedriveplc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medclair AB3.00m-285.13k6.84m14.00--1.8350.362.28-0.0435-0.04350.51340.60350.63181.394.452,859,714.00-6.00-11.20-7.34-12.9563.1369.51-9.50-26.940.9761-11.650.0053--60.1352.1444.27--24.59--
Bio-View Ltd7.36m81.12k7.08m--77.161.1615.180.96120.00320.00320.25680.21630.82892.335.48--0.91323.451.234.5761.4858.711.104.202.15--0.1138--19.296.58-34.75--8.77--
Lifeloc Technologies Inc7.35m-19.24k7.54m37.00--1.5743.701.03-0.0099-0.00993.802.481.121.8314.33251,850.30-0.29250.2981-0.33540.340542.2840.75-0.2620.32451.89--0.166--9.992.03145.11-1.09-54.22--
Titan Logix Corp3.70m-333.94k7.86m----0.8178--2.12-0.0204-0.02040.2190.58690.3572.376.94---3.220.6038-3.350.626147.2652.34-9.022.1617.45--0.045--43.576.69-92.63---22.16--
Phoslock Environmental Technologies Ltd1.51m-5.15m8.14m40.00--1.64--5.41-0.0158-0.01580.00460.01530.16132.163.55---55.13---66.97---81.68---341.76--2.82-405.840.051---51.35---184.79------
TOKYO KOKI CO LTD16.86m456.32k8.36m123.0018.311.1014.020.49612.7812.78471.95213.200.94672.654.3527,361,140.002.560.59054.120.934435.9932.332.710.63641.2517.150.30980.0010.16-8.75112.97-29.83-32.65--
Scanway SA1.25m-560.58k8.52m59.00--2.83--6.84-2.26-2.265.0112.110.3387.382.93109,601.20-15.21---16.67--46.64---45.01--2.01-220.400.00--153.63---921.77------
Genedrive PLC272.00k-5.00m8.83m43.00--1.65--32.45-0.0407-0.04070.00220.00980.0658--1.606,325.58-120.84-97.55-197.86-128.51-----1,837.50-797.031.36-7.490.0789--12.24-50.95-10.16--16.72--
PZ Cormay SA16.26m-1.18m9.28m225.00--0.8854--0.5705-0.0729-0.07291.000.64610.87472.184.89375,240.00-6.39-12.12-9.76-17.1840.0639.19-7.31-16.500.7754-11.970.0765---3.673.3335.43---3.97--
Tedea Technologicl Dvlpmnt and Atmtn Ltd128.15k-1.62m10.58m2.00--2.79--82.59-1.38-1.380.10943.240.0145--6.14---18.35-7.85-21.67-14.08-----1,264.63-42.99----0.146--300.66-63.2049.42---27.42--
Electro-Sensors Inc6.90m260.13k10.89m35.0041.931.0032.581.580.09610.09612.554.020.60952.487.03250,114.302.301.242.431.2949.1552.433.772.0215.41--0.00---5.252.68175.00--16.95--
Holmarc Opto-Mechatronics Ltd-943.45m-943.45m10.93m--------------------------------------------------38.12--129.49------
Scientific Industries Inc8.51m-6.91m10.93m63.00--1.10--1.29-1.13-1.131.341.200.67621.199.31171,263.50-54.96---63.27--44.53---81.28--3.19--0.00--------------
Data as of Jun 14 2024. Currency figures normalised to Genedrive PLC's reporting currency: UK Pound GBX

Institutional shareholders

40.86%Per cent of shares held by top holders
HolderShares% Held
Peel Hunt LLPas of 11 Jun 2024103.69m33.60%
Hargreaves Lansdown Asset Management Ltd.as of 01 Jan 20225.48m1.78%
Jarvis Investment Management Ltd.as of 14 Jun 20232.95m0.96%
IG Markets Ltd.as of 01 Jan 20222.74m0.89%
Rathbones Investment Management Ltd.as of 01 Jan 20222.35m0.76%
HSBC Global Asset Management (UK) Ltd.as of 01 Jan 20222.21m0.71%
BGF Investment Management Ltd.as of 05 Feb 20211.91m0.62%
Walker Crips Investment Management Ltd.as of 01 Jan 20221.90m0.61%
M&G Investment Management Ltd.as of 05 Feb 20201.76m0.57%
Unicorn Asset Management Ltd.as of 31 May 20241.15m0.37%
More ▼
Data from 31 Mar 2024 - 11 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.